Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2004 Nov-Dec;24(6):4169-73.

Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma.

Author information

  • 1Department of Experimental Medicine and Pathology, University of Rome "La Sapienza", Rome, Italy.

Abstract

BACKGROUND:

We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy.

PATIENTS AND METHODS:

One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically.

RESULTS:

FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p = 0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p = 0.10). PTNM stage (p < 0.0001) was the only significant prognostic marker for overall survival.

CONCLUSION:

FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care.

PMID:
15736468
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk